当前位置: X-MOL首页SCI期刊查询及投稿分析系统 › Annals of Medicine杂志
Annals of Medicine
基本信息
期刊名称 Annals of Medicine
ANN MED
期刊ISSN 0785-3890
期刊官方网站 https://www.tandfonline.com/journals/iann20
是否OA Yes
出版商 Informa Healthcare
出版周期 Bi-monthly
文章处理费 登录后查看
始发年份 1969
年文章数 524
影响因子 4.9(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学3区 MEDICINE, GENERAL & INTERNAL 医学:内科3区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 4.9 1.306 1.232
Medicine
General Medicine
103/636 83%
补充信息
自引率 2%
H-index 104
SCI收录状况 Science Citation Index Expanded
官方审稿时间 登录后查看
网友分享审稿时间 数据统计中,敬请期待。
接受率 登录后查看
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0785-3890%5BISSN%5D
投稿指南
期刊投稿网址 https://rp.tandfonline.com/submission/
收稿范围
Annals of Medicine is an online, open access, international journal publishing across 33 areas of medicine and is part of our Elevate Series. This means that you will receive a concierge-level publishing experience, including dedicated support from our expert in-house Editorial team, with guaranteed response times of within 48 hours.

The journal promotes collaboration across therapy areas and the open sharing of research. Combined with its scope covering translational medicine to clinical practice, Annals of Medicine is the home for researchers dedicated to supporting medical professionals in advancing practice for patients worldwide.

Accepting original research articles, review articles, clinical trials, protocols, case series and commentaries, the journal welcomes the submission of negative and null results, and reproducibility studies. Letters to the Editor are also considered and should discuss an analysis of an article previously published in Annals of Medicine.

Case reports are not accepted. Case series must review a minimum of 5 cases and will be considered where they provide novel insight on a disease or disease subtype.

When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors' own data through replication in an original sample. Consideration of studies utilizing publicly available data is at the discretion of the Editor.

Pharmacological studies based solely on in silico analyses without experimental validation are not considered.

Bibliometric analyses and scoping reviews are not considered. 

The journal welcomes submissions to the following sections:

    Addiction
    Anesthesiology
    Cardiology & Cardiovascular Disorders
    Clinical Pathology
    Dermatology
    Emergency Medicine
    Endocrinology
    Gastroenterology
    Geriatrics
    Hematology
    Hepatology
    Immunology
    Infectious Diseases
    Medical Education
    Medical Genetics & Genomics
    Nephrology
    Neurology
    Nutrition
    Oncology
    Ophthalmology
    Pediatrics
    Pharmacology
    Pregnancy, Childbirth & Women's Health
    Primary Care
    Psychiatry
    Public Health
    Pulmonary Medicine
    Physical Medicine & Rehabilitation
    Rheumatology
    Sports Medicine & Musculoskeletal Disorders
    Surgery
    Toxicology
    Urology

Peer review statement
All submitted manuscripts are subject to initial appraisal by the Editorial Team and, if found suitable for further consideration, to single anonymized peer review by independent, expert referees.

According to the STM definitions and terminology for peer review practices, the following summary describes the peer review processes for this journal: 

Standard Submissions to the journal - Single Anonymized Peer Review

Identity transparency: single anonymized

Reviewer interacts with: Editor

Review information published: None

Post publication commenting: None


Submission included in the ChinaXiv/biomedRxiv Open Review Pilot – Open Peer Review

Submissions which are included in the ChinaXiv/biomedRxiv Open Review pilot will be subject to initial appraisal by the Editorial team and, if found suitable for consideration, to open peer review by independent, expert referees. Under this open peer review pilot model:

    All identities are visible to each other (Decision-making Editor, Reviewer, Author);
    Reviewer and Author interacts with Decision-making Editor only;
    All reviewer reports are published on ChinaXiv/biomedRxiv;
    All submitted manuscripts and revised versions are published on ChinaXiv/biomedRxiv;
    Editor communication with Author (e.g., Editor decision letter) are also published on ChinaXiv/biomedRxiv;
    Manuscripts which have been peer reviewed and accepted will be published in Annals of Medicine.

Identity transparency: all identities visible

Reviewer interacts with: Editor

Review information published: Review reports, Submitted manuscript, Reviewer identities, Author/Editor communication, Editor identities (all published on ChinaXiv/biomedRxiv platform)

Post publication commenting: None
收录体裁
投稿指南 https://www.tandfonline.com/action/authorSubmission?show=instructions&journalCode=iann20
投稿模板
参考文献格式
编辑信息

                                
我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug